Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients.

Breast cancer research and treatment - 1 Dec 2021

Thorén Linda, Eriksson Mikael, Lindh Jonatan D, Czene Kamila, Bergh Jonas, Eliasson Erik, Hall Per, Margolin Sara

Abstract excerpt

PURPOSE: Change in mammographic density has been suggested to be a proxy of tamoxifen response. We investigated the effect of additional adjuvant systemic therapy and CYP2D6 activity on MD change in a cohort of tamoxifen-treated pre- and postmenopausal breast cancer patients. METHODS: Swedish breast cancer patients (n = 699) operated 2006-2014, genotyped for CYP2D6, having at least three months postoperative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Density

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Chemotherapy, Adjuvant

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 34570302
DOI: 10.1007/s10549-021-06386-2
PMCID: PMC8558195

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients.PMID 34570302Read ↗

Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment.Semantic proximity Read ↗

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.Semantic proximity Read ↗

Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years.Semantic proximity Read ↗

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.Semantic proximity Read ↗

Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis.Semantic proximity Read ↗

CYP2D6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer?Semantic proximity Read ↗

Tamoxifen Dose Escalation in CYP2D6 Poor Metabolizer Breast Cancer Patients and Associated Side EffectsSemantic proximity Read ↗

Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene.Semantic proximity Read ↗

Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical TrialsSemantic proximity Read ↗

CYP2D6 does not impact on breast cancer-free survival in Southeast Mexican patients under tamoxifen treatment.Semantic proximity Read ↗

CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.Semantic proximity Read ↗

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.